American Journal of Clinical Oncology: Cancer Clinical Trials 1982-Aug
Phase II trial of bruceantin in metastatic breast carcinoma.
只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
关键词
抽象
A phase II evaluation of bruceantin was carried out in 15 patients with refractory metastatic breast cancer. All patients had received extensive prior therapy including adriamycin, cytoxan, 5-FU, methotrexate, and a vinca alkaloid. Except for two patients with stable disease, no complete or partial response was observed. Drug toxicity, mainly nonhematologic, was severe, with nausea, vomiting, mild hypotension, and fever being the most frequently encountered.